Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ettenberg

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Mabs|January 12, 2016
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugatesKalli C Catcott, Molly A McShea, Carl Uli Bialucha, et al.
Plos One|May 4, 2022
BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activityTaylor L Hickman, Eugene Choi, Kathleen R Whiteman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
Mabs|December 9, 2014
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase inductionHeather A Huet, Joseph D Growney, Jennifer A Johnson, et al.
Leukemia|August 22, 2015
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myelomaR H Prabhala, M Fulciniti, D Pelluru, et al.
Plos One|September 18, 2015
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Plos One|January 6, 2016
Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid TumorsTinya Abrams, Anu Connor, Christie Fanton, et al.
Cancer Research|August 10, 2013
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulinAndrew P Garner, Carl U Bialucha, Elizabeth R Sprague, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Mabs|January 12, 2016
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugatesKalli C Catcott, Molly A McShea, Carl Uli Bialucha, et al.
Plos One|May 4, 2022
BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activityTaylor L Hickman, Eugene Choi, Kathleen R Whiteman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
Mabs|December 9, 2014
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase inductionHeather A Huet, Joseph D Growney, Jennifer A Johnson, et al.
Leukemia|August 22, 2015
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myelomaR H Prabhala, M Fulciniti, D Pelluru, et al.
Plos One|September 18, 2015
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Plos One|January 6, 2016
Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesAnupama Reddy, Joseph D Growney, Nick S Wilson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid TumorsTinya Abrams, Anu Connor, Christie Fanton, et al.
Cancer Research|August 10, 2013
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulinAndrew P Garner, Carl U Bialucha, Elizabeth R Sprague, et al.
Pageof 10